Neurocrine Biosciences (NASDAQ:NBIX) Stock Gets Price Target Bump from Canaccord Genuity Group

Neurocrine Biosciences (NASDAQ:NBIX) had its target price upped by research analysts at Canaccord Genuity Group from $210.00 to $220.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price objective would suggest a potential upside of 51.36% from the stock’s current price.

A number of other research analysts have also weighed in on NBIX. Wedbush raised their price target on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a research note on Monday, August 3rd. Wall Street Zen lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. TD Cowen increased their target price on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, July 31st. Truist Financial raised their target price on Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $198.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $201.82.

Neurocrine Biosciences Trading Down 0.5%

NASDAQ NBIX opened at $145.35 on Tuesday. The stock has a market capitalization of $14.77 billion, a price-to-earnings ratio of 21.31, a PEG ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences has a twelve month low of $122.14 and a twelve month high of $186.12. The stock has a 50-day moving average of $146.49 and a 200 day moving average of $147.45.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the business posted $2.04 earnings per share. The firm’s revenue for the quarter was up 41.3% on a year-over-year basis. Equities analysts predict that Neurocrine Biosciences will post 7.72 EPS for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other news, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at $6,729,417.60. This represents a 5.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David W. Boyer sold 826 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the sale, the insider owned 8,722 shares of the company’s stock, valued at $1,373,278.90. This represents a 8.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Basecamp Wealth Advisors LLC increased its stake in Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares during the last quarter. Raleigh Capital Management Inc. lifted its stake in shares of Neurocrine Biosciences by 561.8% in the 3rd quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock valued at $32,000 after purchasing an additional 191 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences in the 1st quarter valued at $33,000. Ascentis Independent Advisors acquired a new position in shares of Neurocrine Biosciences in the 1st quarter valued at $40,000. Finally, TrinityBridge Ltd purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth $45,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter results: Neurocrine reported adjusted earnings of $3.29 per share, up from $2.04 a year earlier and above consensus estimates ranging from $1.91 to $2.67. Revenue increased 41.3% year over year to approximately $1.12 billion, exceeding the roughly $1.04 billion estimate. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales exceeded $1 billion for the first time: Management attributed the milestone to strong demand across its portfolio of medicines, indicating continued commercial momentum and a broader revenue base. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: INGREZZA guidance raised: Neurocrine increased its 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The upgraded outlook reinforces expectations for sustained demand for the company’s leading commercial product. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings-call presentations and transcripts provide additional detail on quarterly performance, product demand, and the company’s outlook. Investors will likely focus on whether the strong growth and raised guidance can continue into 2027. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.